Skip to main content

Ankylosing Spondylitis

Podcast microphone headphones
Day 4: ACR 2019 Podcast
RheumNow
Podcast microphone headphones
Day 2 (part two) ACR 2019 Podcast
RheumNow
Podcast microphone headphones
Day 2 (part one) Podcast
RheumNow
Podcast microphone headphones
Non-radiographic axSpA: Dr. Philip Robinson

Dr. Robinson highlights a presentation on non-radiographic axial spondyloarthritis presented at the 2019 ACR/ARP annual meeting in Atlanta. 

Panel Presentation: Spondyloarthritis

Drs. Jack Cush, Christopher Ritchlin, Sophia Ramiro, Lianne Gensler, and Jessica Walsh discuss interesting new trials and data presented in ankylosing spondylitis and spondyloarthritis at the 2019 ACR/ARP annual meeting in Atlanta.  

sunset bench exercise
Muscle Loss and Frailty in Rheumatic Disease
Paul Sufka, MD
“If exercise could be purchased in a pill, it would be the single most widely prescribed and beneficial medicine in the nation.” —Robert H. Butler, MD, first director of the National Institute on…
RT @synovialjoints: Results from2 anti-IL-17 agents Secukinumab and Ixekizumab in non-radiographic axial Spondyloarthritis poster #L2 and a…

Dr. Antoni Chan synovialjoints

8 months 3 weeks ago

Results from2 anti-IL-17 agents Secukinumab and Ixekizumab in non-radiographic axial Spondyloarthritis poster #L2 and abstract #2729 is promising as treatment options for patients #ACR19 @RheumNow

RT @synovialjoints: The ASAS40 and all major secondary endpoints for Ixekizumab Q4W and Q2W were met at Wk 16 and Wk 52 with no unexpected…

Dr. Antoni Chan synovialjoints

8 months 3 weeks ago

The ASAS40 and all major secondary endpoints for Ixekizumab Q4W and Q2W were met at Wk 16 and Wk 52 with no unexpected safety findings. IXE superior to PBO for improving signs, symptoms, and inflammation on MRI in pts with nr-axSpA abstract #2729 #ACR19 @RheumNow

RT @synovialjoints: PREVENT trial of Secukinumabnr-axSpA. SEC 150 mg loading and no loading dose provided significant improvement in signs…

Dr. Antoni Chan synovialjoints

8 months 3 weeks ago

PREVENT trial of Secukinumabnr-axSpA. SEC 150 mg loading and no loading dose provided significant improvement in signs and symptoms of nr-axSpA through Wk 16. The safety profile of SEC was consistent with the established safety profile across indications #L2 #ACR19 @RheumNow

New Treatments for Axial Spondyloarthritis: Dr. Antoni Chan

Dr. Chan discusses several studies on spondyloarthritis presented at the 2019 ACR/ARP annual meeting in Atlanta. 

RT @DrKanikaMonga: Abstract #0626Are there really differences between non-radiographic and radiographic axial spondyloarthritis? Data from…

Kanika Monga, MD DrKanikaMonga

8 months 3 weeks ago

Abstract #0626 Are there really differences between non-radiographic and radiographic axial spondyloarthritis? Data from the Spanish Atlas #ACR19 @RheumNow https://t.co/hg3U2QjpFp

RT @MaeveGamble: Abstr#2273: higher placental transfer antiTNFs=ADA,IFX,GOL. Less transfer=CTZ,ETN. No ⬆️ in infxns in offspring, even with…

Maeve Gamble MaeveGamble

8 months 3 weeks ago

Abstr#2273: higher placental transfer antiTNFs=ADA,IFX,GOL. Less transfer=CTZ,ETN. No ⬆️ in infxns in offspring, even with 3rd tri exposure. Potential trend for ⬆️ in serious infxns (>/=1 hosp adm 1st yr of life) with high placental transfer antiTNFs, not sig. #ACR2019 @RheumNow https://t.co/qEIl9lxlv1

RT @hausmannMD: Secukinumab: a human IgG1κ monoclonal antibody that binds to IL-17AASAS40: a composite measure including patient global,…

Jonathan Hausmann MD hausmannMD

8 months 3 weeks ago

Secukinumab: a human IgG1κ monoclonal antibody that binds to IL-17A ASAS40: a composite measure including patient global, pain, function, and inflammation In patients with nr-AxSpA, secukinumab improved ASAS40 through week 52, compared to placebo Dr. Deodhar #ACR19 @RheumNow https://t.co/yLwt47w2wr

RT @philipcrobinson: Video from @gensler_MD on AS and nr-axSpA studies presented at #ACR19 @rheumnow https://t.co/fcn9zCxouU via @YouTube

Philip Robinson philipcrobinson

8 months 3 weeks ago

Video from @gensler_MD on AS and nr-axSpA studies presented at #ACR19 @rheumnow https://t.co/fcn9zCxouU via @YouTube

RT @synovialjoints: 5-year effectiveness of TNFi in patients with early axSpA shown, male gender, HLAB27 positive and presence of at least…

Dr. Antoni Chan synovialjoints

8 months 3 weeks ago

5-year effectiveness of TNFi in patients with early axSpA shown, male gender, HLAB27 positive and presence of at least one objective sign of inflammation or structural damage are more frequently associated with effectiveness #2776 by Molto #ACR19 @RheumNow

RT @philipcrobinson: @_connectedcare @RheumNow @ACRheum My pearls (so far)1. Use vitamin A to reduce SEs w MTX2. Try doxycycline for refr…

Philip Robinson philipcrobinson

8 months 3 weeks ago

@_connectedcare @RheumNow @ACRheum My pearls (so far) 1. Use vitamin A to reduce SEs w MTX 2. Try doxycycline for refractory calcinosis in scleroderma 3. Use MTX with pegloticase to reduce infusion reactions 4. Anti-IL17 has activity in nr-axSpA 5. Patients think opiates are more effective than SNRIs or TCAs in FM

RT @MaeveGamble: Abstr#2729: 303 pts randomized. More pts achieved ASAS40 at Wk 16: IXE Q2W (40%), IXE Q4W (35%) vs PBO (19%, p< 0.01) and…

Maeve Gamble MaeveGamble

8 months 3 weeks ago

Abstr#2729: 303 pts randomized. More pts achieved ASAS40 at Wk 16: IXE Q2W (40%), IXE Q4W (35%) vs PBO (19%, p< 0.01) and at Wk 52: IXE Q2W (31%), IXE Q4W (30%) vs PBO (13%, p< 0.01). Blocking IL-17A is a potential treatment option for patients with nr-axSpA. #ACR19 @RheumNow

Dr Atul Deodhar wows the crowd at #ACR19 showing abtract #2729 Ixekizumab in Non-Radiographic Axial Spondyloarthritis: Phase 3 Trial showing IXE is ef

Dr. John Cush RheumNow

8 months 3 weeks ago

Dr Atul Deodhar wows the crowd at #ACR19 showing abtract #2729 Ixekizumab in Non-Radiographic Axial Spondyloarthritis: Phase 3 Trial showing IXE is effective by ASAS40. https://t.co/Bcb20FYNoH

RT @_connectedcare: Upadacitinib in ASAnd here’s the Safety Slide#ACR19 @rheumnow Abst2728 https://t.co/fpjhrjGp0N

Dr Irwin Lim _connectedcare

8 months 3 weeks ago

Upadacitinib in AS And here’s the Safety Slide #ACR19 @rheumnow Abst2728 https://t.co/fpjhrjGp0N

×